Dr. Ansell Discusses Immune Evasion in Lymphoma

Video

In Partnership With:

Stephen M. Ansell, MD, PhD, chair of the Lymphoma Group at Mayo Clinic, discusses immune invasion in lymphoma.

Stephen M. Ansell, MD, PhD, chair of the Lymphoma Group at Mayo Clinic, discusses immune invasion in lymphoma.

Ansell says that one of the biggest challenges in lymphoma is that many immune cells are present in the tumor, but they are not killing the tumor cells. This begs the question of how the tumor cell hides from the immune system as well as it does. There are many barriers to a good response in lymphoma, Ansell says. The immune cells are worn out from being persistently activated, and sometimes there are other cells in the area that can suppress their activity.

There are proteins that either are made on the tumor cell, or proteins like cytokines that activate the immune system, that exhaust the immune system over time. Ansell says the goal in answering this question of immune evasion is getting the T cell to kill the tumor cell efficiently. There are multiple strategies under evaluation to try to reach this goal.

Related Videos
Jorge J. Castillo, MD,
Heinz-Josef Lenz, MD, FACP
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Omid Hamid, MD, professor, medicine, Cedars-Sinai; director, Clinical Research and Immunotherapy, director, Cutaneous Oncology and Melanoma, The Angeles Clinic and Research Institute
Christina L. Roland, MD, MS, FACS
Ashish Saxena, MD, PhD
Shruti Tiwari, MD
Scott Kopetz, MD, PhD, FACP
Katharina Hoebel, MD, PhD
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine